ENDRA Life Sciences (NDRA) Stock Price, News & Analysis

Company Overview

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Key Stats

• Today's Range: $4.09 to $4.32
• 50-Day Range: $3.41 to $8.84
• 52-Week Range: $2.90 to $22.68
• Volume: 9,192 shs
• Average Volume: 58,006 shs
• Market Capitalization: $3.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Buy

ENDRA Life Sciences Stock Analysis - MarketRank™

ENDRA Life Sciences scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

ENDRA Life Sciences has a consensus price target of $50.00, representing about 1,071.0% upside from its current price of $4.27.

Amount of Analyst Coverage

ENDRA Life Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ENDRA Life Sciences are expected to grow in the coming year, from ($47.46) to ($15.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ENDRA Life Sciences is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ENDRA Life Sciences is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ENDRA Life Sciences has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.02% of the float of ENDRA Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

ENDRA Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ENDRA Life Sciences has recently decreased by 1.54%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ENDRA Life Sciences does not currently pay a dividend.

Dividend Growth

ENDRA Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.02% of the float of ENDRA Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

ENDRA Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ENDRA Life Sciences has recently decreased by 1.54%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for NDRA on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

2 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.04% of the stock of ENDRA Life Sciences is held by insiders.

Percentage Held by Institutions

Only 1.19% of the stock of ENDRA Life Sciences is held by institutions.

NDRA Stock Analysis - Frequently Asked Questions

How have NDRA shares performed this year?

ENDRA Life Sciences' stock was trading at $6.26 at the start of the year. Since then, NDRA shares have decreased by 31.8% and is now trading at $4.27.

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($1.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.27) by $0.56.

When did ENDRA Life Sciences' stock split?

ENDRA Life Sciences shares reverse split on the morning of Tuesday, August 20th 2024.The 1-50 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did ENDRA Life Sciences IPO?

ENDRA Life Sciences (NDRA) raised $10 million in an initial public offering (IPO) on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO.

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ENDRA Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ENDRA Life Sciences investors own include Bionano Genomics (BNGO), Cocrystal Pharma (COCP), AMC Entertainment (AMC), Plug Power (PLUG), Mustang Bio (MBIO), SNDL (SNDL) and BIOLASE (BIOL).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/05/2025
• Next Earnings (Estimated): 11/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NDRA
• CIK: 1681682
• Web: www.endrainc.com
• Phone: (734) 335-0468
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ENDRA Life Sciences: $50.00
• High Price Target: $50.00
• Low Price Target: $50.00
• Potential Upside/Downside: +1,071.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($33.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -194.14%
• Return on Assets: -127.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.21
• Quick Ratio: 3.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.77 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 750,000
• Free Float: 753,000
• Market Cap: $3.20 million
• Optionable: Not Optionable
• Beta: -0.14